Acarbose 50 mg Metformin 500 mg Tablet PCD Pharma Franchise

Description

ACARWISE-M 50/500 Tablet contains Acarbose 50 mg Metformin 500 mg Tablet, combining an alpha-glucosidase inhibitor with a biguanide antidiabetic agent. This combination may be prescribed with dietary management and physical activity to improve blood glucose control in patients with type 2 diabetes mellitus when clinically appropriate. Both ingredients act through different mechanisms to support glycaemic management.

Acarbose delays carbohydrate digestion and glucose absorption in the intestine, helping reduce post-meal blood glucose elevations. Metformin primarily reduces hepatic glucose production and improves insulin sensitivity. The combination may therefore help address different aspects of blood glucose regulation under appropriate medical supervision.

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical trade partners. Businesses searching for an Acarbose 50 mg + Metformin 500 mg Tablets manufacturer India can enquire about product availability, approved specifications, manufacturing details and relevant quality documentation.

For procurement teams evaluating an Acarbose 50 mg + Metformin 500 mg Tablets manufacturer and supplier India, it is important to verify the formulation, manufacturing source, applicable regulatory approvals, batch documentation and commercial supply terms before placing an order.

2. Key Ingredients

Acarbose 50 mg Metformin 500 mg Tablet

Acarbose – 50 mg

Acarbose belongs to the alpha-glucosidase inhibitor class. It acts primarily in the small intestine by inhibiting enzymes involved in carbohydrate digestion. This delays the breakdown of complex carbohydrates and reduces the rise in blood glucose following meals.

Metformin 500 mg

Metformin belongs to the biguanide class of antidiabetic medicines. It primarily reduces glucose production by the liver and improves the body’s response to insulin. It does not directly stimulate pancreatic insulin secretion.

The complementary mechanisms of these ingredients may support blood glucose management in eligible patients with type 2 diabetes, subject to the prescriber’s assessment.

For businesses researching an Acarbose 50 mg + Metformin 500 mg pharmaceutical company India, relevant procurement considerations include composition accuracy, product authorization, quality assurance, packaging and traceability.

Companies seeking an Acarbose 50 mg + Metformin 500 mg medicine manufacturer India should verify the manufacturing facility’s regulatory status, approved product specifications, batch release procedures and applicable quality standards.

3. Key Benefits
Complementary mechanisms: Combines an intestinal carbohydrate-digestion inhibitor with a medicine that primarily reduces hepatic glucose production.
Post-meal glucose management: Acarbose helps moderate postprandial blood glucose elevations.
Fasting glucose management: Metformin helps reduce excessive hepatic glucose production and improves insulin sensitivity.
Oral treatment option: Provides an oral formulation for eligible patients when the combination is prescribed.
Individualized diabetes care: May be incorporated into a broader treatment plan involving diet, exercise and blood glucose monitoring.
Different pharmacological actions: The ingredients act through distinct mechanisms, which may offer complementary glucose-lowering effects.

These benefits are dependent on the patient’s clinical condition, adherence, treatment response and the advice of a qualified healthcare professional. The combination is not a substitute for dietary management or regular diabetes monitoring.

Pharmaceutical buyers looking for an Acarbose 50 mg + Metformin 500 mg supplier India should verify product authenticity, packaging, batch traceability, shelf life and supply continuity.

An Acarbose 50 mg + Metformin 500 mg Tablet wholesaler and distributor India enquiry may include current stock, minimum order quantities, delivery coverage, applicable licensing and commercial terms.

Businesses requiring an Acarbose 50 mg + Metformin 500 mg bulk supplier India should request a formal quotation and confirm batch availability, transportation conditions, storage requirements and quality documentation.

An Acarbose 50 mg + Metformin 500 mg pharmaceutical distributor India should esTabletlish the applicable distribution permissions, product availability and approved promotional claims before commencing commercial activities.

4. How Does It Work?

The combination works through two complementary mechanisms.

Acarbose: Reversibly inhibits intestinal alpha-glucosidase enzymes and pancreatic alpha-amylase, slowing carbohydrate digestion and delaying glucose absorption after meals.

Metformin: Reduces hepatic glucose production, decreases intestinal glucose absorption to some extent and improves insulin sensitivity, supporting greater peripheral glucose utilization.

Together, these actions may help improve blood glucose control in selected patients with type 2 diabetes. The formulation does not directly stimulate insulin secretion. The suitability of the combination depends on individual treatment requirements and the approved prescribing information.

5. Directions for Use
Dosage: Take only as prescribed by a doctor. The dose and frequency must be determined according to the patient’s clinical condition, glucose response, kidney function, tolerance and other medicines.
Administration with meals: Acarbose is generally taken with the first bite of a main meal. Metformin is commonly administered with meals to reduce gastrointestinal discomfort. Follow the exact instructions for the prescribed formulation.
Regular timing: Follow the prescribed schedule consistently and avoid changing the dose without medical advice.
Treatment adherence: Continue dietary management, physical activity and blood glucose monitoring as recommended.
Missed dose: Follow the advice of the doctor or pharmacist. Do not double the next dose to compensate for a missed dose.
Combination therapy: Inform the prescriber about other antidiabetic medicines because additional treatment may affect the risk of hypoglycaemia and other adverse effects.

The listed strengths do not esTabletlish the appropriate dose for every patient. Confirm whether the particular product is an approved fixed-dose combination and follow its approved prescribing information.

6. Possible Side Effects

Possible adverse effects include:

Flatulence and increased intestinal gas
Abdominal discomfort or bloating
Diarrhoea
Nausea
Vomiting
Altered bowel habits
Reduced appetite or other gastrointestinal discomfort

Acarbose commonly causes gastrointestinal symptoms because it delays carbohydrate digestion. Metformin may also cause digestive disturbances, particularly when treatment begins or the dose changes.

Hypoglycaemia: The risk may increase when the combination is used with insulin or sulfonylureas. If hypoglycaemia occurs in a patient taking acarbose, oral glucose (dextrose) is generally preferred over sucrose for initial correction because sucrose digestion is delayed.

Serious warning: Metformin is associated with a rare but potentially life-threatening risk of lactic acidosis, particularly in patients with significant renal impairment or certain acute illnesses. Seek urgent medical care for severe weakness, unusual muscle pain, breathing difficulty, unusual drowsiness or other concerning symptoms.

Persistent diarrhoea, severe abdominal symptoms, allergic reactions or other serious adverse effects require prompt medical evaluation.

7. Safety Information
Medical supervision: Use only under the supervision of a qualified healthcare professional.
Contraindications: Acarbose may be contraindicated in certain intestinal disorders, intestinal obstruction, diabetic ketoacidosis, cirrhosis or known hypersensitivity. Metformin is contraindicated in severe renal impairment and certain conditions associated with meTabletolic acidosis. Check the approved product information for complete contraindications.
Kidney function: Metformin requires assessment of renal function before and during treatment. The combination may be unsuitable for patients with significant kidney impairment.
Liver health: Liver disease and conditions that increase the risk of lactic acidosis require clinical assessment. Acarbose is contraindicated in cirrhosis under commonly referenced prescribing information.
Pregnancy and breastfeeding: Obtain specialist medical advice before use during pregnancy, when planning pregnancy or while breastfeeding. Diabetes treatment may need reassessment.
Drug interactions: Inform the doctor about all prescription medicines, over-the-counter products and supplements, particularly insulin and other glucose-lowering medicines.
Medical procedures: Tell the healthcare team about metformin treatment before iodinated contrast imaging or surgery, as temporary interruption may be necessary in certain circumstances.
Dehydration and acute illness: Severe dehydration, serious infection, low oxygen states or other acute conditions may increase treatment risks and require urgent medical advice.
Storage: Store in the original packaging according to the approved product label, protected from excessive heat and moisture and out of children’s reach.

This information is educational and does not replace professional medical advice or approved prescribing information.

8. B2B Pharmaceutical Business Enquiries

CardianCare focuses on the cardiac and diabetic healthcare segment and provides a contact point for pharmaceutical trade enquiries. Interested distributors, wholesalers and eligible business partners should confirm the availability of this specific formulation and the relevant commercial terms directly with the company.

Businesses researching an Acarbose 50 mg + Metformin 500 mg PCD pharma franchise India opportunity should enquire about eligible product portfolios, territorial availability, partner requirements and applicable commercial conditions.

For an Acarbose 50 mg + Metformin 500 mg Tablets PCD pharma franchise enquiry, prospective partners can request details of distribution eligibility, minimum order requirements, product documentation, promotional support and territory-specific arrangements.

Companies exploring an Acarbose 50 mg + Metformin 500 mg Tablet PCD franchise should confirm whether this formulation is included in the current programme before making investment or promotional commitments.

Businesses evaluating Acarbose 50 mg + Metformin 500 mg third party manufacturing India services should first esTabletlish whether the proposed company offers such arrangements. Relevant checks include manufacturing authorization, approved specifications, applicable GMP compliance, minimum batch quantities and quality documentation.

An Acarbose 50 mg + Metformin 500 mg Tablet third party manufacturer India enquiry should cover the manufacturing facility’s regulatory status, quality systems, batch release requirements, packaging specifications and contractual responsibilities.

Companies researching Acarbose 50 mg + Metformin 500 mg contract manufacturing India should discuss formulation requirements, product approvals, technical documentation, quality agreements, regulatory responsibilities and commercial feasibility with the proposed manufacturing partner.

For more information about ACARWISE-M 50/500 Tablet (Acarbose 50 mg + Metformin 500 mg), Click Here